Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study

QR Code

Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study

Hui-Chuan Sun,1,&ast; Zhi-Yong Huang,2,&ast; Tianfu Wen,3,&ast; Lianxin Liu,4,&ast; Xiao-Dong Zhu,1,&ast; Erlei Zhang,2 Chuan Li,3 Xiaoyun Zhang,3 Jiabei Wang,4 Jia Fan,1 Jian Zhou1 1Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer I...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sun HC, Huang ZY, Wen T, Liu L, Zhu XD, Zhang E, Li C, Zhang X, Wang J, Fan J, Zhou J
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-05-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	lenvatinib hepatocellular carcinoma recurrence adjuvant therapy
Online Access:	https://www.dovepress.com/adjuvant-lenvatinib-for-high-risk-cnlc-iibiiia-hepatocellular-carcinom-peer-reviewed-fulltext-article-JHC
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Survival Benefit of Adjuvant Treatment with Huaier Granules Plus Lenvatinib in Hepatocellular Carcinoma Patients with Tumors Greater Than 5 cm After Radical Hepatectomy
by: Liu C, et al.
Published: (2025-07-01)

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
by: Yuki Ohya, et al.
Published: (2020-12-01)

Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation
by: Yuan Yuan, et al.
Published: (2025-12-01)

Pulmonary hemorrhage and hemopneumothorax following the administration of lenvatinib for lung metastasis from hepatocellular carcinoma
by: Kazuya Kishimoto, et al.
Published: (2025-01-01)

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study
by: Lu C, et al.
Published: (2025-07-01)

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
by: Masahiro Matsuki, et al.
Published: (2018-06-01)

Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Yongfa Lei, et al.
Published: (2025-07-01)

Combining Hepatic Arterial Interventional Therapies with Lenvatinib and Programmed Cell Death-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Single-Center, Real-World Study
by: Shen X, et al.
Published: (2025-07-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report
by: Haruhiko Yamazaki, et al.
Published: (2023-03-01)

Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
by: Akabane M, et al.
Published: (2025-06-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer—is it justified?
by: R.D. Peixoto, et al.
Published: (2025-09-01)

Clinical experience in the neoadjuvant treatment of unresectable differentiated thyroid cancer with the lenvatinib
by: E. B. Vasilyeva, et al.
Published: (2024-06-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report
by: Kimimasa Sasaki, et al.
Published: (2021-12-01)

Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report
by: Shinkuro Yamamoto, et al.
Published: (2025-09-01)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
by: Jitong Zhou, et al.
Published: (2025-07-01)

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01)

Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
by: E. A. Khachaturyan, et al.
Published: (2025-05-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Hyper-Relapse Disease is a Special Pattern of Relapse of Hepatocellular Carcinoma After Curative Hepatectomy: A Retrospective Cohort Study
by: Yang ZL, et al.
Published: (2025-07-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

Positive results of treatment of adenocystic carcinoma of the parotid salivary gland with lenvatinib
by: I. A. Filippov, et al.
Published: (2024-11-01)

Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma
by: Xia Y, et al.
Published: (2025-07-01)

Immunological adjuvants : report of a WHO Scientific Group.
Published: (1976)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01)

Assessment of the Adjuvant Effects of Lentinan on the Tuberculosis Subunit Vaccine BG
by: Shuai Zhou, et al.
Published: (2025-05-01)

Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer
by: M. V. Volkonskiy, et al.
Published: (2025-05-01)

COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01)

Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy
by: Cheng Xu, et al.
Published: (2025-07-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan
by: Sh. Kh. Gantsev, et al.
Published: (2020-11-01)

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

Immunization with Complete Freund’s Adjuvant Reveals Trained Immunity-like Features in A/J Mice
by: Kiruthiga Mone, et al.
Published: (2025-07-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Advance in chicken coccidiosis vaccine and its adjuvant
by: DU Ai-fang, et al.
Published: (2009-01-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)